Go to Home

Search

-Advanced Search   -Search Guidelines

Clin Exp Otorhinolaryngol.  2023 Nov;16(4):291-307. 10.21053/ceo.2023.00458.

Guidelines for the Use of Botulinum Toxin in Otolaryngology From the Korean Society of Laryngology, Phoniatrics and Logopedics Guideline Task Force

Affiliations
  • 1Department of Otorhinolaryngology-Head and Neck Surgery, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea
  • 2Department of Otorhinolaryngology-Head and Neck Surgery, National Cancer Center, Goyang, Korea
  • 3Department of Otorhinolaryngology-Head and Neck Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
  • 4Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyung Hee University, Seoul, Korea
  • 5Department of Otorhinolaryngology-Head and Neck Surgery, Dong-A University College of Medicine, Busan, Korea
  • 6Department of Otorhinolaryngology-Head and Neck Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • 7Department of Otorhinolaryngology-Head and Neck Surgery, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea
  • 8Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University, Daegu, Korea
  • 9Department of Otorhinolaryngology-Head and Neck Surgery, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea
  • 10Department of Otorhinolaryngology-Head and Neck Surgery, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea

Abstract

The Korean Society of Laryngology, Phoniatrics and Logopedics created a task force to establish clinical practice guidelines for the use of botulinum toxin (BT) in otolaryngology. We selected 10 disease categories: spasmodic dysphonia, essential vocal tremor, vocal fold granuloma, bilateral vocal fold paralysis, Frey’s syndrome, sialocele, sialorrhea, cricopharyngeal dysfunction, chronic sialadenitis, and first bite syndrome. To retrieve all relevant papers, we searched the CORE databases with predefined search strategies, including Medline (PubMed), Embase, the Cochrane Library, and KoreaMed. The committee reported 13 final recommendations with detailed evidence profiles. The guidelines are primarily aimed at all clinicians applying BT to the head and neck area. In addition, the guidelines aim to promote an improved understanding of the safe and effective use of BT by policymakers and counselors, as well as in patients scheduled to receive BT injections.

Keyword

Botulinum Toxins; Dysphonia; Vocal Cord Paralysis; Salivary Gland; Esophageal Sphincter, Upper; Cricopharyngeal Dysfunction

Figure

  • Fig. 1. Flow diagram for the literature search. KQ, key question.


Reference

1. Hyodo M, Hirose K, Nagao A, Nakahira M, Kobayashi T. Botulinum toxin therapy for spasmodic dysphonia in Japan: the history and an update. Toxins (Basel). 2022; Jul. 14(7):451.
2. Newland DP, Novakovic D, Richards AL. Voice tremor and botulinum neurotoxin therapy: a contemporary review. Toxins (Basel). 2022; Nov. 14(11):773.
3. Schneider I, Thumfart WF, Pototschnig C, Eckel HE. Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol. 1994; Jan. 103(1):31–5.
4. Nasri S, Sercarz JA, McAlpin T, Berke GS. Treatment of vocal fold granuloma using botulinum toxin type A. Laryngoscope. 1995; Jun. 105(6):585–8.
5. Drobik C, Laskawi R. Frey’s syndrome: treatment with botulinum toxin. Acta Otolaryngol. 1995; May. 115(3):459–61.
6. Jost WH, Baumer T, Laskawi R, Slawek J, Spittau B, Steffen A, et al. Therapy of sialorrhea with botulinum neurotoxin. Neurol Ther. 2019; Dec. 8(2):273–88.
7. Li Y, Garrett G, Zealear D. Current treatment options for bilateral vocal fold paralysis: a state-of-the-art review. Clin Exp Otorhinolaryngol. 2017; Sep. 10(3):203–12.
8. Vargas H, Galati LT, Parnes SM. A pilot study evaluating the treatment of postparotidectomy sialoceles with botulinum toxin type A. Arch Otolaryngol Head Neck Surg. 2000; Mar. 126(3):421–4.
9. Strohl MP, Chang CF, Ryan WR, Chang JL. Botulinum toxin for chronic parotid sialadenitis: a case series and systematic review. Laryngoscope Investig Otolaryngol. 2021; May. 6(3):404–13.
10. Ali MJ, Orloff LA, Lustig LR, Eisele DW. Botulinum toxin in the treatment of first bite syndrome. Otolaryngol Head Neck Surg. 2008; Nov. 139(5):742–3.
11. Lee BJ, Lee JC, Lee YO, Wang SG, Kim HJ. Novel treatment of first bite syndrome using botulinum toxin type A. Head Neck. 2009; Aug. 31(8):989–93.
12. Chiu SY, Burns MR, Malaty IA. An update on botulinum toxin in neurology. Neurol Clin. 2021; Feb. 39(1):209–29.
13. Anandan C, Jankovic J. Botulinum toxin in movement disorders: an update. Toxins (Basel). 2021; Jan. 13(1):42.
14. Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017; Aug. 32(8):1131–8.
15. Smith TJ, Hill KK, Raphael BH. Historical and current perspectives on Clostridium botulinum diversity. Res Microbiol. 2015; May. 166(4):290–302.
16. Oh HM, Chung ME. Botulinum toxin for neuropathic pain: a review of the literature. Toxins (Basel). 2015; Aug. 7(8):3127–54.
17. Qerama E, Fuglsang-Frederiksen A, Jensen TS. The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol. 2010; Oct. 23(5):602–10.
18. Kim JE, Song EJ, Choi GS, Lew BL, Sim WY, Kang H. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plast Reconstr Surg. 2015; Mar. 135(3):732–41.
19. Cha W, Jang JY, Wang SG, Kang JH, Jo MG. Liquid-type botulinum toxin type A in adductor spasmodic dysphonia: a prospective pilot study. J Voice. 2017; May. 31(3):378.
20. Scaglione F. Conversion ratio between Botox(R), Dysport(R), and Xeomin(R) in clinical practice. Toxins (Basel). 2016; Mar. 8(3):65.
21. Ministry of Food and Drug Safety (KR). Notification of change of permission according to drug re-examination results [Allergan Korea, 50 units of Botox (Clostridium botulinum toxin type A)] [Internet]. Ministry of Food and Drug Safety; 2018 [cited 2023 Oct 31]. Available from: https://nedrug.mfds.go.kr/bbs/58/3137/#.
22. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005; Sep. 53(3):407–15.
23. Lee SW. Botulinum toxin for other head and neck lesions. J Korean Soc Laryngol Phoniatr Logop. 2012; 23(2):104–10.
24. Samizadeh S, De Boulle K. Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol. 2018; May. 11:273–87.
25. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013; Apr. 66(4):408–14.
26. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007; Feb. 7:10.
27. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 1998; Oct. 108(10):1435–41.
28. Watts C, Nye C, Whurr R. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review. Clin Rehabil. 2006; Feb. 20(2):112–22.
29. Boutsen F, Cannito MP, Taylor M, Bender B. Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res. 2002; Jun. 45(3):469–81.
30. Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope. 1991; Jun. 101(6 Pt 1):630–4.
31. Hyodo M, Nagao A, Asano K, Sakaguchi M, Mizoguchi K, Omori K, et al. Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: a multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison/open-label clinical trial. Eur J Neurol. 2021; May. 28(5):1548–56.
32. Faham M, Ahmadi A, Silverman E, Harouni GG, Dabirmoghaddam P. Quality of life after botulinum toxin injection in patients with adductor spasmodic dysphonia; a systematic review and meta-analysis. J Voice. 2021; Mar. 35(2):271–83.
33. Courey MS, Garrett CG, Billante CR, Stone RE, Portell MD, Smith TL, et al. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Ann Otol Rhinol Laryngol. 2000; Sep. 109(9):819–22.
34. van Esch BF, Wegner I, Stegeman I, Grolman W. Effect of botulinum toxin and surgery among spasmodic dysphonia patients. Otolaryngol Head Neck Surg. 2017; Feb. 156(2):238–54.
35. Dharia I, Bielamowicz S. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort. Laryngoscope. 2020; Nov. 130(11):2659–62.
36. Adams SG, Hunt EJ, Irish JC, Charles DA, Lang AE, Durkin LC, et al. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. J Otolaryngol. 1995; Dec. 24(6):345–51.
37. Lee SJ, Kang MS, Choi HS, Lim JY. Alternating unilateral versus bilateral injections of botulinum toxin for the treatment of adductor spasmodic dysphonia. Otolaryngol Head Neck Surg. 2021; Apr. 164(4):815–20.
38. Upile T, Elmiyeh B, Jerjes W, Prasad V, Kafas P, Abiola J, et al. Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study. Head Face Med. 2009; Oct. 5:20.
39. Bielamowicz S, Stager SV, Badillo A, Godlewski A. Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia. J Voice. 2002; Mar. 16(1):117–23.
40. Langeveld TP, Drost HA, Baatenburg de Jong RJ. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol. 1998; Apr. 107(4):280–4.
41. Koriwchak MJ, Netterville JL, Snowden T, Courey M, Ossoff RH. Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia. Laryngoscope. 1996; Dec. 106(12 Pt 1):1476–81.
42. Kim JW, Park JH, Park KN, Lee SW. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study. ScientificWorldJournal. 2014; 2014:327928.
43. Fulmer SL, Merati AL, Blumin JH. Efficacy of laryngeal botulinum toxin injection: comparison of two techniques. Laryngoscope. 2011; Sep. 121(9):1924–8.
44. Rosow DE, Parikh P, Vivero RJ, Casiano RR, Lundy DS. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia. Otolaryngol Head Neck Surg. 2013; Jun. 148(6):1003–6.
45. Novakovic D, Waters HH, D’Elia JB, Blitzer A. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. Laryngoscope. 2011; Mar. 121(3):606–12.
46. Bielamowicz S, Squire S, Bidus K, Ludlow CL. Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol. 2001; May. 110(5 Pt 1):406–12.
47. Woodson G, Hochstetler H, Murry T. Botulinum toxin therapy for abductor spasmodic dysphonia. J Voice. 2006; Mar. 20(1):137–43.
48. Klein AM, Stong BC, Wise J, DelGaudio JM, Hapner ER, Johns MM 3rd. Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia. Otolaryngol Head Neck Surg. 2008; Sep. 139(3):421–3.
49. Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018; Jan. 33(1):75–87.
50. Haubenberger D, Hallett M. Essential tremor. N Engl J Med. 2018; May. 378(19):1802–10.
51. Sulica L, Louis ED. Clinical characteristics of essential voice tremor: a study of 34 cases. Laryngoscope. 2010; Mar. 120(3):516–28.
52. Guglielmino G, Moraes BT, Villanova LC, Padovani M, Biase NG. Comparison of botulinum toxin and propranolol for essential and dystonic vocal tremors. Clinics (Sao Paulo). 2018; Jul. 73:e87.
53. Sharma S, Pandey S. Treatment of essential tremor: current status. Postgrad Med J. 2020; Feb. 96(1132):84–93.
54. Hertegard S, Granqvist S, Lindestad PA. Botulinum toxin injections for essential voice tremor. Ann Otol Rhinol Laryngol. 2000; Feb. 109(2):204–9.
55. Kaye R, Blitzer A. Chemodenervation of the larynx. Toxins (Basel). 2017; Nov. 9(11):356.
56. Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, et al. Botulinum toxin type A for treating voice tremor. Arch Neurol. 2004; Sep. 61(9):1416–20.
57. Gurey LE, Sinclair CF, Blitzer A. A new paradigm for the management of essential vocal tremor with botulinum toxin. Laryngoscope. 2013; Oct. 123(10):2497–501.
58. Orbelo DM, Duffy JR, Hughes Borst BJ, Ekbom D, Maragos NE. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor. J Voice. 2014; Jan. 28(1):123–7.
59. Benninger MS, Smith LJ. Noncosmetic uses of botulinum toxin in otolaryngology. Cleve Clin J Med. 2015; Nov. 82(11):729–32.
60. Hoffman HT, Overholt E, Karnell M, McCulloch TM. Vocal process granuloma. Head Neck. 2001; Dec. 23(12):1061–74.
61. Martins RH, Dias NH, Soares CS, Gramuglia AC. Treatment of laryngeal granulomas. Int Arch Otorhinolaryngol. 2019; Jul. 23(3):e322–4.
62. Shoffel-Havakuk H, Sadoughi B, Sulica L, Johns MM 3rd. In-office procedures for the treatment of benign vocal fold lesions in the awake patient: a contemporary review. Laryngoscope. 2019; Sep. 129(9):2131–8.
63. Rudman JR, McGee CS, Diaz J, Rosow DE. Assessing the utility of non-surgical treatments in the management of vocal process granulomas. J Laryngol Otol. 2020; Jan. 134(1):68–73.
64. Karkos PD, George M, Van Der Veen J, Atkinson H, Dwivedi RC, Kim D, et al. Vocal process granulomas: a systematic review of treatment. Ann Otol Rhinol Laryngol. 2014; May. 123(5):314–20.
65. Yilmaz T, Kayahan B, Gunaydin RO, Kuscu O, Sozen T. Botulinum toxin a for treatment of contact granuloma. J Voice. 2016; Nov. 30(6):741–3.
66. Pham Q, Campbell R, Mattioni J, Sataloff R. Botulinum toxin injections into the lateral cricoarytenoid muscles for vocal process granuloma. J Voice. 2018; May. 32(3):363–6.
67. Hamdan AL, Khalifee E, Jaffal H, Ghanem A. Interarytenoid botulinum toxin A injection for the treatment of vocal process granuloma. J Laryngol Otol. 2019; Dec. 133(12):1041–5.
68. Fink DS, Achkar J, Franco RA, Song PC. Interarytenoid botulinum toxin injection for recalcitrant vocal process granuloma. Laryngoscope. 2013; Dec. 123(12):3084–7.
69. Orloff LA, Goldman SN. Vocal fold granuloma: successful treatment with botulinum toxin. Otolaryngol Head Neck Surg. 1999; Oct. 121(4):410–3.
70. Pham J, Yin S, Morgan M, Stucker F, Nathan CO. Botulinum toxin: helpful adjunct to early resolution of laryngeal granulomas. J Laryngol Otol. 2004; Oct. 118(10):781–5.
71. Ho CF, Lee YC, Hsin LJ, Lee LA, Li HY, Fang TJ. Low-dose LEMGguided botulinum toxin type A injection for intractable vocal process granulomas. J Voice. 2022; Mar. 36(2):277–82.
72. Lei L, Yang H, Zhang X, Ren J. Comparison of the effects of esomeprazole plus mosapride citrate and botulinum toxin A on vocal process granuloma. Am J Otolaryngol. 2017; Sep-Oct. 38(5):593–97.
73. Lee SW, Hong HJ, Choi SH, Sun DI, Park YH, Lee BJ, et al. Comparison of treatment modalities for contact granuloma: a nationwide multicenter study. Laryngoscope. 2014; May. 124(5):1187–91.
74. Damrose EJ, Damrose JF. Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma. J Laryngol Otol. 2008; Aug. 122(8):824–8.
75. Yilmaz T, Suslu N, Atay G, Ozer S, Gunaydin RO, Bajin MD. Recurrent contact granuloma: experience with excision and botulinum toxin injection. JAMA Otolaryngol Head Neck Surg. 2013; Jun. 139(6):579–83.
76. Ma L, Xiao Y, Ye J, Yang Q, Wang J. Analysis of therapeutic methods for treating vocal process granulomas. Acta Otolaryngol. 2015; Mar. 135(3):277–82.
77. Kraimer KL, Husain I. Updated medical and surgical treatment for common benign laryngeal lesions. Otolaryngol Clin North Am. 2019; Aug. 52(4):745–57.
78. Czesak MA, Osuch-Wojcikiewicz E, Niemczyk K. Methods of surgical treatment of bilateral vocal fold paralysis. Endokrynol Pol. 2020; 71(4):350–8.
79. Nawka T, Gugatschka M, Kolmel JC, Muller AH, Schneider-Stickler B, Yaremchuk S, et al. Therapy of bilateral vocal fold paralysis: real world data of an international multi-center registry. PLoS One. 2019; Apr. 14(4):e0216096.
80. Ongkasuwan J, Courey M. The role of botulinum toxin in the management of airway compromise due to bilateral vocal fold paralysis. Curr Opin Otolaryngol Head Neck Surg. 2011; Dec. 19(6):444–8.
81. Ekbom DC, Garrett CG, Yung KC, Johnson FL, Billante CR, Zealear DL, et al. Botulinum toxin injections for new onset bilateral vocal fold motion impairment in adults. Laryngoscope. 2010; Apr. 120(4):758–63.
82. Zealear DL, Billante CR, Courey MS, Sant’Anna GD, Netterville JL. Electrically stimulated glottal opening combined with adductor muscle Botox blockade restores both ventilation and voice in a patient with bilateral laryngeal paralysis. Ann Otol Rhinol Laryngol. 2002; Jun. 111(6):500–6.
83. Marchese MR, Bussu F, Settimi S, Scarano E, Almadori G, Galli J. Not only gustatory sweating and flushing: signs and symptoms associated to the Frey syndrome and the role of botulinum toxin A therapy. Head Neck. 2021; Mar. 43(3):949–55.
84. Baek CH, Chung MK, Jeong HS, Son YI, Jung SC, Jeon HK, et al. Questionnaire evaluation of sequelae over 5 years after parotidectomy for benign diseases. J Plast Reconstr Aesthet Surg. 2009; May. 62(5):633–8.
85. Neumann A, Rosenberger D, Vorsprach O, Dazert S. The incidence of Frey syndrome following parotidectomy: results of a survey and follow-up. HNO. 2011; Feb. 59(2):173–8.
86. Vahtsevanos K, Chatziavramidis A, Papadiochos IY, Koloutsos G, Stefanidis A, Kitikidou K, et al. Prevention of Frey’s syndrome with the use of porcine dermal collagen graft: retrospective analysis of 76 “formal” parotidectomies for benign pathologies. Ann Otol Rhinol Laryngol. 2021; Sep. 130(9):1036–43.
87. Eckardt A, Kuettner C. Treatment of gustatory sweating (Frey’s syndrome) with botulinum toxin A. Head Neck. 2003; Aug. 25(8):624–8.
88. De Virgilio A, Costantino A, Russo E, Ferreli F, Pellini R, Petruzzi G, et al. Different surgical strategies in the prevention of Frey syndrome: a systematic review and meta-analysis. Laryngoscope. 2021; Aug. 131(8):1761–8.
89. Li C, Yang X, Pan J, Shi Z, Li L. Graft for prevention of Frey syndrome after parotidectomy: a systematic review and meta-analysis of randomized controlled trials. J Oral Maxillofac Surg. 2013; Feb. 71(2):419–27.
90. Sanabria A, Kowalski LP, Bradley PJ, Hartl DM, Bradford CR, de Bree R, et al. Sternocleidomastoid muscle flap in preventing Frey’s syndrome after parotidectomy: a systematic review. Head Neck. 2012; Apr. 34(4):589–98.
91. Hays LL. The Frey syndrome: a review and double blind evaluation of the topical use of a new anticholinergic agent. Laryngoscope. 1978; Nov. 88(11):1796–824.
92. de Bree R, van der Waal I, Leemans CR. Management of Frey syndrome. Head Neck. 2007; Aug. 29(8):773–8.
93. Jansen S, Jerowski M, Ludwig L, Fischer-Krall E, Beutner D, Grosheva M. Botulinum toxin therapy in Frey’s syndrome: a retrospective study of 440 treatments in 100 patients. Clin Otolaryngol. 2017; Apr. 42(2):295–300.
94. Laccourreye O, Muscatelo L, Naude C, Bonan B, Brasnu D. Botulinum toxin type A for Frey’s syndrome: a preliminary prospective study. Ann Otol Rhinol Laryngol. 1998; Jan. 107(1):52–5.
95. Naumann M, Zellner M, Toyka KV, Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol. 1997; Dec. 42(6):973–5.
96. Laccourreye O, Akl E, Gutierrez-Fonseca R, Garcia D, Brasnu D, Bonan B. Recurrent gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin type A: incidence, management, and outcome. Arch Otolaryngol Head Neck Surg. 1999; Mar. 125(3):283–6.
97. de Bree R, Duyndam JE, Kuik DJ, Leemans CR. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg. 2009; Mar. 135(3):287–90.
98. Beerens AJ, Snow GB. Botulinum toxin A in the treatment of patients with Frey syndrome. Br J Surg. 2002; Jan. 89(1):116–9.
99. Xie S, Wang K, Xu T, Guo XS, Shan XF, Cai ZG. Efficacy and safety of botulinum toxin type A for treatment of Frey’s syndrome: evidence from 22 published articles. Cancer Med. 2015; Nov. 4(11):1639–50.
100. Hartl DM, Julieron M, LeRidant AM, Janot F, Marandas P, Travagli JP. Botulinum toxin A for quality of life improvement in post-parotidectomy gustatory sweating (Frey’s syndrome). J Laryngol Otol. 2008; Oct. 122(10):1100–4.
101. Maharaj S, Mungul S, Laher A. Botulinum toxin A is an effective therapeutic tool for the management of parotid sialocele and fistula: a systematic review. Laryngoscope Investig Otolaryngol. 2020; Jan. 5(1):37–45.
102. Lee YC, Park GC, Lee JW, Eun YG, Kim SW. Prevalence and risk factors of sialocele formation after partial superficial parotidectomy: a multi-institutional analysis of 357 consecutive patients. Head Neck. 2016; Apr. 38 Suppl 1:E941–4.
103. Marchese-Ragona R, Marioni G, Restivo DA, Staffieri A. The role of botulinum toxin in postparotidectomy fistula treatment: a technical note. Am J Otolaryngol. 2006; May-Jun. 27(3):221–4.
104. Costan VV, Dabija MG, Ciofu ML, Sulea D, Popescu E, Boisteanu O. A functional approach to posttraumatic salivary fistula treatment: the use of botulinum toxin. J Craniofac Surg. 2019; May/Jun. 30(3):871–5.
105. Melville JC, Stackowicz DJ, Jundt JS, Shum JW. Use of Botox (OnabotulinumtoxinA) for the treatment of parotid sialocele and fistula after extirpation of buccal squamous cell carcinoma with immediate reconstruction using microvascular free flap: a report of 3 cases. J Oral Maxillofac Surg. 2016; Aug. 74(8):1678–86.
106. Lee DJ, Lee YM, Park HJ, Lee JW, Cha W. Intraoperative botulinum toxin injection for superficial partial parotidectomy: a prospective pilot study. Clin Otolaryngol. 2021; Sep. 46(5):998–1004.
107. Laskawi R, Winterhoff J, Kohler S, Kottwitz L, Matthias C. Botulinum toxin treatment of salivary fistulas following parotidectomy: follow-up results. Oral Maxillofac Surg. 2013; Dec. 17(4):281–5.
108. Send T, Bertlich M, Eichhorn KW, Bootz F, Jakob M. management and follow-up results of salivary fistulas treated with botulinum toxin. Laryngoscope. 2019; Feb. 129(2):403–8.
109. Mazlan M, Rajasegaran S, Engkasan JP, Nawawi O, Goh KJ, Freddy SJ. A double-blind randomized controlled trial investigating the most efficacious dose of botulinum toxin-A for sialorrhea treatment in Asian adults with neurological diseases. Toxins (Basel). 2015; Sep. 7(9):3758–70.
110. Varley LP, Denieffe S, O’Gorman C, Murphy A, Gooney M. A systematic review of noninvasive and invasive sialorrhoea management. J Clin Nurs. 2019; Dec. 28(23-24):4190–206.
111. Vashishta R, Nguyen SA, White DR, Gillespie MB. Botulinum toxin for the treatment of sialorrhea: a meta-analysis. Otolaryngol Head Neck Surg. 2013; Feb. 148(2):191–6.
112. Wu KP, Ke JY, Chen CY, Chen CL, Chou MY, Pei YC. Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study. J Child Neurol. 2011; Jul. 26(7):838–43.
113. Bekkers S, van Ulsen KJ, Adang EM, Scheffer AR, van den Hoogen FJ. Cost-effectiveness of botulinum neurotoxin A versus surgery for drooling: a randomized clinical trial. Dev Med Child Neurol. 2020; Nov. 62(11):1302–8.
114. Ruiz-Roca JA, Pons-Fuster E, Lopez-Jornet P. Effectiveness of the botulinum toxin for treating sialorrhea in patients with Parkinson’s disease: a systematic review. J Clin Med. 2019; Mar. 8(3):317.
115. Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009; Feb. 39(2):137–43.
116. Hughes A, Choi S. Does intraglandular injection of botulinum toxin improve pediatric sialorrhea. Laryngoscope. 2018; Jul. 128(7):1513–4.
117. Van der Burg JJ, Jongerius PH, Van Hulst K, Van Limbeek J, Rotteveel JJ. Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and care. Dev Med Child Neurol. 2006; Feb. 48(2):103–7.
118. Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013; Jun. 67:141–52.
119. Gonzalez-L MD, Martinez C, Bori Y Fortuny I, Suso-Vergara S. Factors in the efficacy, safety, and impact on quality of life for treatment of drooling with botulinum toxin type A in patients with cerebral palsy. Am J Phys Med Rehabil. 2017; Feb. 96(2):68–76.
120. Jost WH, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki A, et al. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks. Parkinsonism Relat Disord. 2020; Jan. 70:23–30.
121. Bekkers S, Delsing CP, Kok SE, van Hulst K, Erasmus CE, Scheffer AR, et al. Randomized controlled trial comparing botulinum vs surgery for drooling in neurodisabilities. Neurology. 2019; Mar. 92(11):e1195–204.
122. Lungren MP, Halula S, Coyne S, Sidell D, Racadio JM, Patel MN. Ultrasound-guided botulinum toxin type A salivary gland injection in children for refractory sialorrhea: 10-year experience at a large tertiary children’s hospital. Pediatr Neurol. 2016; Jan. 54:70–5.
123. Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson’s disease: a prospective double-blind trial. Mov Disord. 2012; Feb. 27(2):219–26.
124. Isaacson SH, Ondo W, Jackson CE, Trosch RM, Molho E, Pagan F, et al. Safety and efficacy of rimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial. JAMA Neurol. 2020; Apr. 77(4):461–9.
125. Mitchell SD, Sidiropoulos C. Therapeutic applications of botulinum neurotoxin for autonomic symptoms in Parkinson’s disease: an updated review. Toxins (Basel). 2021; Mar. 13(3):226.
126. Shehee L, O’Rourke A, Garand KL. The role of radiation therapy and botulinum toxin injections in the management of sialorrhea in patients with amyotrophic lateral sclerosis: a systematic review. J Clin Neuromuscul Dis. 2020; Jun. 21(4):205–21.
127. Squires N, Humberstone M, Wills A, Arthur A. The use of botulinum toxin injections to manage drooling in amyotrophic lateral sclerosis/motor neurone disease: a systematic review. Dysphagia. 2014; Aug. 29(4):500–8.
128. Young T, Hopewell S. Methods for obtaining unpublished data. Cochrane Database Syst Rev. 2011; Nov. 2011(11):MR000027.
129. Abdel Jalil AA, Katzka DA, Castell DO. Approach to the patient with dysphagia. Am J Med. 2015; Oct. 128(10):1138.
130. Cook IJ, Kahrilas PJ. AGA technical review on management of oropharyngeal dysphagia. Gastroenterology. 1999; Feb. 116(2):455–78.
131. Kuhn MA, Belafsky PC. Management of cricopharyngeus muscle dysfunction. Otolaryngol Clin North Am. 2013; Dec. 46(6):1087–99.
132. Martino R, McCulloch T. Therapeutic intervention in oropharyngeal dysphagia. Nat Rev Gastroenterol Hepatol. 2016; Nov. 13(11):665–79.
133. Dewan K, Santa Maria C, Noel J. Cricopharyngeal achalasia: management and associated outcomes-a scoping review. Otolaryngol Head Neck Surg. 2020; Dec. 163(6):1109–13.
134. Lee SY, Seo HG, Paik NJ. Botulinum toxin injection for dysphagia: a blinded retrospective videofluoroscopic swallowing study analysis. Am J Phys Med Rehabil. 2009; Jun. 88(6):491–4.
135. Chavez YH, Ciarleglio MM, Clarke JO, Nandwani M, Stein E, Roland BC. Upper esophageal sphincter abnormalities: frequent finding on high-resolution esophageal manometry and associated with poorer treatment response in achalasia. J Clin Gastroenterol. 2015; Jan. 49(1):17–23.
136. Moerman MB. Cricopharyngeal Botox injection: indications and technique. Curr Opin Otolaryngol Head Neck Surg. 2006; Dec. 14(6):431–6.
137. Blitzer A, Brin MF. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia. Otolaryngol Head Neck Surg. 1997; Mar. 116(3):328–30.
138. Ahsan SF, Meleca RJ, Dworkin JP. Botulinum toxin injection of the cricopharyngeus muscle for the treatment of dysphagia. Otolaryngol Head Neck Surg. 2000; May. 122(5):691–5.
139. Alberty J, Oelerich M, Ludwig K, Hartmann S, Stoll W. Efficacy of botulinum toxin A for treatment of upper esophageal sphincter dysfunction. Laryngoscope. 2000; Jul. 110(7):1151–6.
140. Haapaniemi JJ, Laurikainen EA, Pulkkinen J, Marttila RJ. Botulinum toxin in the treatment of cricopharyngeal dysphagia. Dysphagia. 2001; Summer. 16(3):171–5.
141. Shaw GY, Searl JP. Botulinum toxin treatment for cricopharyngeal dysfunction. Dysphagia. 2001; Summer. 16(3):161–7.
142. Parameswaran MS, Soliman AM. Endoscopic botulinum toxin injection for cricopharyngeal dysphagia. Ann Otol Rhinol Laryngol. 2002; Oct. 111(10):871–4.
143. Chao SS, Graham SM, Hoffman HT. Management of pharyngoesophageal spasm with Botox. Otolaryngol Clin North Am. 2004; Jun. 37(3):559–66.
144. Zaninotto G, Marchese Ragona R, Briani C, Costantini M, Rizzetto C, Portale G, et al. The role of botulinum toxin injection and upper esophageal sphincter myotomy in treating oropharyngeal dysphagia. J Gastrointest Surg. 2004; Dec. 8(8):997–1006.
145. Murry T, Wasserman T, Carrau RL, Castillo B. Injection of botulinum toxin A for the treatment of dysfunction of the upper esophageal sphincter. Am J Otolaryngol. 2005; May-Jun. 26(3):157–62.
146. Kelly EA, Koszewski IJ, Jaradeh SS, Merati AL, Blumin JH, Bock JM. Botulinum toxin injection for the treatment of upper esophageal sphincter dysfunction. Ann Otol Rhinol Laryngol. 2013; Feb. 122(2):100–8.
147. Regan J, Murphy A, Chiang M, McMahon BP, Coughlan T, Walshe M. Botulinum toxin for upper oesophageal sphincter dysfunction in neurological swallowing disorders. Cochrane Database Syst Rev. 2014; May. 2014(5):CD009968.
148. Kocdor P, Siegel ER, Tulunay-Ugur OE. Cricopharyngeal dysfunction: a systematic review comparing outcomes of dilatation, botulinum toxin injection, and myotomy. Laryngoscope. 2016; Jan. 126(1):135–41.
149. Miles A, Allen JE. Management of oropharyngeal neurogenic dysphagia in adults. Curr Opin Otolaryngol Head Neck Surg. 2015; Dec. 23(6):433–9.
150. Terre R, Panades A, Mearin F. Botulinum toxin treatment for oropharyngeal dysphagia in patients with stroke. Neurogastroenterol Motil. 2013; Nov. 25(11):896–e702.
151. Restivo DA, Marchese-Ragona R, Patti F, Solaro C, Maimone D, Zappala G, et al. Botulinum toxin improves dysphagia associated with multiple sclerosis. Eur J Neurol. 2011; Mar. 18(3):486–90.
152. Restivo DA, Marchese-Ragona R, Lauria G, Squatrito S, Gullo D, Vigneri R. Botulinum toxin treatment for oropharyngeal dysphagia associated with diabetic neuropathy. Diabetes Care. 2006; Dec. 29(12):2650–3.
153. Kim DY, Park CI, Ohn SH, Moon JY, Chang WH, Park SW. Botulinum toxin type A for poststroke cricopharyngeal muscle dysfunction. Arch Phys Med Rehabil. 2006; Oct. 87(10):1346–51.
154. Abu-Ghanem S, Sung CK, Junlapan A, Kearney A, DiRenzo E, Dewan K, et al. Endoscopic management of postradiation dysphagia in head and neck cancer patients: a systematic review. Ann Otol Rhinol Laryngol. 2019; Aug. 128(8):767–73.
155. Jeong SH, Kim YJ, Kim YJ, Park KD, Kim EJ, Chung JW, et al. Endoscopic botulinum toxin injection for treatment of pharyngeal dysphagia in patients with cricopharyngeal dysfunction. Scand J Gastroenterol. 2018; Oct-Nov. 53(10-11):1201–5.
156. Xie M, Zeng P, Wan G, An D, Tang Z, Li C, et al. The effect of combined guidance of botulinum toxin injection with ultrasound, catheter balloon, and electromyography on neurogenic cricopharyngeal dysfunction: a prospective study. Dysphagia. 2022; Jun. 37(3):601–11.
157. Kim MS, Kim GW, Rho YS, Kwon KH, Chung EJ. Office-based electromyography-guided botulinum toxin injection to the cricopharyngeus muscle: optimal patient selection and technique. Ann Otol Rhinol Laryngol. 2017; May. 126(5):349–56.
158. Huai J, Hou Y, Guan J, Zhang Y, Wang Y, Zhang X, et al. Botulinum toxin A injection using esophageal balloon radiography combined with CT guidance for the treatment of cricopharyngeal dysphagia. Dysphagia. 2020; Aug. 35(4):630–5.
159. Sharma SD, Kumar G, Eweiss A, Chatrath P, Kaddour H. Endoscopic-guided injection of botulinum toxin into the cricopharyngeus muscle: our experience. J Laryngol Otol. 2015; Oct. 129(10):990–5.
160. Kim MJ, Min YW. Endoscopic management of dysphagia. Korean J Gastroenterol. 2021; Feb. 77(2):77–83.
161. Woisard-Bassols V, Alshehri S, Simonetta-Moreau M. The effects of botulinum toxin injections into the cricopharyngeus muscle of patients with cricopharyngeus dysfunction associated with pharyngolaryngeal weakness. Eur Arch Otorhinolaryngol. 2013; Mar. 270(3):805–15.
162. Ashman A, Dale OT, Baldwin DL. Management of isolated cricopharyngeal dysfunction: systematic review. J Laryngol Otol. 2016; Jul. 130(7):611–5.
163. Kwon SY, Chun KJ, Kil HK, Oh KH, Kim C, Jang SJ, et al. Botulinum toxin injection for chronic parotitis: a multi-center and prospective trial. Laryngoscope. 2021; Jun. 131(6):E1903–9.
164. Capaccio P, Torretta S, Osio M, Minorati D, Ottaviani F, Sambataro G, et al. Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders. Am J Otolaryngol. 2008; SepOct. 29(5):333–8.
165. Netterville JL, Jackson CG, Miller FR, Wanamaker JR, Glasscock ME. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Arch Otolaryngol Head Neck Surg. 1998; Oct. 124(10):1133–40.
166. Cohen SM, Burkey BB, Netterville JL. Surgical management of parapharyngeal space masses. Head Neck. 2005; Aug. 27(8):669–75.
167. Deganello A, Meccariello G, Busoni M, Franchi A, Gallo O. First bite syndrome as presenting symptom of parapharyngeal adenoid cystic carcinoma. J Laryngol Otol. 2011; Apr. 125(4):428–31.
168. Diercks GR, Rosow DE, Prasad M, Kuhel WI. A case of preoperative “first-bite syndrome” associated with mucoepidermoid carcinoma of the parotid gland. Laryngoscope. 2011; Apr. 121(4):760–2.
169. Costales-Marcos M, Lopez Alvarez F, Fernandez-Vanes L, Gomez J, Llorente JL. Treatment of the first bite syndrome. Acta Otorrinolaringol Esp (Engl Ed). 2017; Sep-Oct. 68(5):284–8.
170. Ghosh A, Mirza N. First bite syndrome: our experience with intraparotid injections with botulinum toxin type A. Laryngoscope. 2016; Jan. 126(1):104–7.
171. Sims JR, Suen JY. First bite syndrome: case report of 3 patients treated with botulinum toxin and review of other treatment modalities. Head Neck. 2013; Sep. 35(9):E288–91.
172. Laccourreye O, Werner A, Garcia D, Malinvaud D, Tran Ba Huy P, Bonfils P. First bite syndrome. Eur Ann Otorhinolaryngol Head Neck Dis. 2013; Nov. 130(5):269–73.
173. Persaud R, Garas G, Silva S, Stamatoglou C, Chatrath P, Patel K. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep. 2013; Feb. 4(2):10.
174. Steel SJ, Robertson CE. First bite syndrome: what neurologists need to know. Curr Pain Headache Rep. 2021; Mar. 25(5):31.
175. Amin N, Pelser A, Weighill J. First bite syndrome: our experience of laser tympanic plexus ablation. J Laryngol Otol. 2014; Feb. 128(2):166–8.
Full Text Links
  • CEO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles

Cited

Download

Close

Save citations to file

Download

Close

Email citations

Send Email
recaptcha 영역

Close

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr